Smith & Nephew SNATS Revenue 2006-2018 | SNN

Smith & Nephew SNATS annual/quarterly revenue history and growth rate from 2006 to 2018. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
  • Smith & Nephew SNATS revenue for the quarter ending December 31, 2018 was $0.000B, a NAN% increase year-over-year.
  • Smith & Nephew SNATS revenue for the twelve months ending December 31, 2018 was $0M, a 100% decline year-over-year.
  • Smith & Nephew SNATS annual revenue for 2018 was $4.904B, a 2.92% increase from 2017.
  • Smith & Nephew SNATS annual revenue for 2017 was $4.765B, a 2.06% increase from 2016.
  • Smith & Nephew SNATS annual revenue for 2016 was $4.669B, a 0.76% increase from 2015.
Smith & Nephew SNATS Annual Revenue
(Millions of US $)
2018 $4,904
2017 $4,765
2016 $4,669
2015 $4,634
2014 $4,617
2013 $4,351
2012 $4,137
2011 $4,270
2010 $3,962
2009 $3,772
2008 $3,801
2007 $3,369
2006 $2,779
2005 $2,562
Smith & Nephew SNATS Quarterly Revenue
(Millions of US $)
Q4 2018 $0
Q2 2018 $0
Q4 2017 $0
Q2 2017 $0
Q4 2016 $0
Q4 2015 $0
Q2 2015 $0
Q4 2014 $1,249
Q3 2014 $1,148
Q2 2014 $1,147
Q1 2014 $1,073
Q4 2013 $1,175
Q3 2013 $1,027
Q2 2013 $1,074
Q1 2013 $1,075
Q4 2012 $1,077
Q3 2012 $952
Q2 2012 $1,029
Q1 2012 $1,079
Q4 2011 $1,106
Q3 2011 $1,032
Q2 2011 $1,077
Q1 2011 $1,055
Q4 2010 $1,067
Q3 2010 $941
Q2 2010 $959
Q1 2010 $995
Q4 2009 $1,066
Q3 2009 $915
Q2 2009 $926
Q1 2009 $865
Q4 2008 $960
Q3 2008 $930
Q2 2008 $1,000
Q1 2008 $911
Q4 2007 $967
Q3 2007 $845
Q2 2007 $813
Q1 2007 $744
Q4 2006 $771
Q3 2006 $679
Q2 2006 $686
Q1 2006 $643
Q4 2005 $673
Q3 2005 $609
Q2 2005 $652
Q1 2005 $625
Sector Industry Market Cap Revenue
Medical Medical Products Manufacturing $18.990B $4.904B
Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physicianadvantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment todeliver new levels of healing to patients throughout the world
Stock Name Country Market Cap PE Ratio
Abbott Laboratories (ABT) United States $148.615B 28.85
Medtronic (MDT) Ireland $132.640B 18.95
Stryker (SYK) United States $76.039B 27.14
Boston Scientific (BSX) United States $58.018B 27.81
Baxter (BAX) United States $41.696B 26.28
Zimmer Biomet Holdings (ZBH) United States $23.900B 15.35
ResMed (RMD) United States $17.191B 32.85
Canopy Growth (CGC) Canada $13.701B 0.00
Bio-Rad Laboratories (BIO) United States $8.984B 47.63
Aurora Cannabis (ACB) Canada $7.565B 74.60
Hill-Rom Holdings (HRC) United States $6.984B 21.17
Insulet (PODD) United States $6.926B 504.61
Perrigo (PRGO) Ireland $6.188B 10.46
Haemonetics (HAE) United States $5.977B 48.79
GW Pharmaceuticals (GWPH) United Kingdom $5.182B 0.00
ICU Medical (ICUI) United States $5.138B 30.66
Hutchison China MediTech (HCM) China $3.897B 0.00
Neogen (NEOG) United States $3.107B 50.52
NuVasive (NUVA) United States $2.983B 24.36
Agios Pharmaceuticals (AGIO) United States $2.912B 0.00
National Vision Holdings (EYE) United States $2.413B 51.42
Quidel (QDEL) United States $2.341B 24.29
Aphria (APHA) $1.735B 0.00
Cardiovascular Systems (CSII) United States $1.450B 832.80
HEXO (HEXO) $1.317B 0.00
Phibro Animal Health (PAHC) United States $1.244B 18.64
AtriCure (ATRC) United States $1.171B 0.00
VAREX IMAGING (VREX) United States $1.134B 24.08
Lantheus Holdings (LNTH) United States $1.078B 28.62
OrganiGram Holdings (OGI) Canada $0.947B 0.00
NanoString Technologies (NSTG) United States $0.920B 0.00
PetIQ (PETQ) United States $0.860B 20.88
Quanterix (QTRX) United States $0.818B 0.00
MacroGenics (MGNX) United States $0.801B 0.00
Omeros (OMER) United States $0.762B 0.00
Eagle Pharmaceuticals (EGRX) United States $0.733B 20.55
Cerus (CERS) United States $0.674B 0.00
TG Therapeutics (TGTX) United States $0.601B 0.00
OraSure Technologies (OSUR) United States $0.544B 25.03
LeMaitre Vascular (LMAT) United States $0.542B 26.25
Surmodics (SRDX) United States $0.533B 77.45
Meridian Bioscience (VIVO) United States $0.484B 14.79
Evolus (EOLS) United States $0.390B 0.00
Vapotherm (VAPO) United States $0.368B 0.00
Neptune Technologies & Bioresources Inc (NEPT) Canada $0.355B 0.00
Zynex (ZYXI) United States $0.339B 35.00
Utah Medical Products (UTMD) United States $0.316B 21.87
BioLife Solutions (BLFS) United States $0.286B 89.41
Cytosorbents (CTSO) United States $0.209B 0.00
Bovie Medical (APYX) United States $0.199B 0.00
Owens & Minor (OMI) United States $0.191B 4.04
Rockwell Medical (RMTI) United States $0.178B 0.00
Chimerix (CMRX) United States $0.172B 0.00
Fonar (FONR) United States $0.145B 7.63
Female Health (VERU) United States $0.132B 0.00
BRAINSWAY LTD (BWAY) Israel $0.112B 0.00
Neurotrope (NTRP) United States $0.107B 0.00
Chembio Diagnostics (CEMI) United States $0.102B 0.00
InfuSystems Holdings (INFU) United States $0.088B 0.00
United-Guardian (UG) United States $0.086B 18.98
Surface Oncology (SURF) United States $0.081B 0.00
Oramed Pharmaceuticals (ORMP) United States $0.062B 0.00
ImmuCell (ICCC) United States $0.047B 0.00
Trinity Biotech (TRIB) Ireland $0.040B 13.83
Senestech (SNES) United States $0.037B 0.00
GUARDION HEALTH (GHSI) United States $0.030B 0.00
Cellectar Biosciences (CLRB) United States $0.020B 0.00
Valeritas Holdings (VLRX) United States $0.015B 0.00
Myomo (MYO) United States $0.014B 0.00
Capricor Therapeutics (CAPR) United States $0.011B 0.00
Conatus Pharmaceuticals (CNAT) United States $0.010B 0.00
InVivo Therapeutics Holdings (NVIV) United States $0.007B 0.00
Akers Biosciences Inc (AKER) United States $0.006B 0.00
NeuroMetrix (NURO) United States $0.005B 3.86